A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 314 participants.
Also called NCT03723655
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 314 participants
- Sponsor
- Registry
-
NCT03723655
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Belgium, Czechia, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03723655. Randomized; triple masking; primary purpose treatment. Start 2018-09-27 (actual); primary completion 2026-01-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
- Condition
- Hypertrophic Cardiomyopathy
- Condition
- Obstructive Hypertrophic Cardiomyopathy
- Condition
- Non-obstructive Hypertrophic Cardiomyopathy
- Intervention (Drug)
- mavacamten
- Lead sponsor
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct03723655- Content hash
b35f7bb864f5c65edda16367f6721c0f7df49d7e8f0cf00b00e20be679609264